Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer

Journal of the National Cancer Institute

Volumn 96, Issue 4, 2004, Pages 326-331

  Nemunaitis, John ^a,f   Sterman, Daniel ^b   Jablons, David ^c   Smith II, John W ^d   Fox, Bernard ^d   Maples, Phil ^a   Hamilton, Scott ^e   Borellini, Flavia ^e   Lin, Andy ^e   Morali, Sayeh ^e   Hege, Kristen ^e  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^e CELL GENESYS INC   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TUMOR VACCINE;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASCITES; AUTOTRANSPLANTATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ERYTHEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; GENETIC ENGINEERING; HUMAN; HYPOKALEMIA; INJECTION SITE; LUNG ALVEOLUS CELL CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; UPPER RESPIRATORY TRACT INFECTION; VIRAL GENE DELIVERY SYSTEM;

EID: 10744229445     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh028     Document Type: Article

References (38)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
2. Grunberg S, Kempf R, Itri L, Venturi C, Boswell W, Mitchell M. Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma. Cancer Treat Rep 1985;69:1031-2.
3. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997;80:42-9.
4. Schulof R, Mai D, Nelson M, Paxton H, Cox J, Turner M, et al. Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer. Mol Biother 1988;1:30-6.
5. Perlin E, Oldham RK, Weese JL, Heim W, Reid J, Mills M, et al. Carcinoma of the lung: immunotherapy with intradermal BCG and allogeneic tumor cells. Int J Radiat Oncol Biol Phys 1980;6:1033-9.
6. Stack BH, McSwan N, Stirling JM, Hole DJ, Spilg WG, McHattie I, et al. Autologous x-irradiated tumour cells and percutaneous BCG in operable lung cancer. Thorax 1982; 37:588-93.
7. Souter RG, Gill PG, Gunning AJ, Morris PJ. Failure of specific active immunotherapy in lung cancer. Br J Cancer 1981;44:496-501.
8. Takita H, Takada M, Minowada J, Han T, Edgerton F. Adjuvant immunotherapy of stage III lung carcinoma. New York (NY): Raven Press; 1978.
9. Hollinshead A, Stewart T, Takita H, Dalbow M, Concannon J. Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens [published erratum appears in Cancer 1988;61:1090]. Cancer 1987; 60:1249-62.
10. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
11. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
12. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
13. Aoki T, Tashiro K, Miyatake S, Kinashi T, Nakano T, Oda Y, et al. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicty in vivo. Proc Natl Acad Sci U S A 1992;89:3850-4.
14. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43.
15. Lee CT, Wu S, Ciernik IF, Chen HL, Nadaf-Rahrov S, Gabrilovich D, et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997;8:187-93.
16. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160-8.
17. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger J, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998;95:13141-6.
18. Simons J, Jaffee E, Weber C, Levitsky H, Nelson W, Carducci M, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
19. Jaffee E, Hruban R, Laheru D, Schepers K, Sauter P, Goemann M, et al. Novel allogeneic GM-CSF-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19: 145-56.
20. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21:624-30.
21. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343-50.
22. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997;71:1842-9.
23. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 1992;10:239-53.
24. Jaffee E, Thomas M, Huang A, Hauda K, Levitsky H, Pardoll D. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol 1996;19:176-83.
25. Barkely J, Green M. Bronchioloalveolar carcinoma. J Clin Oncol 1996;14:2377-86.
26. Stinson J, Leibovitz A, Brindley G, Hayward R, Turner R, McCombs W. Filamentous particles in human alveolar cell carcinomas: electron microscopy studies of six cases (preliminary report). J Natl Cancer Inst 1972;49: 1483-93.
27. Min KW, Song J. Virus-like intranuclear particles in bronchiolar-alveolar cell carcinoma. J Iowa Med Soc 1982;72:319-21.
28. Vance R, Crowley J, Livingston R, Gandara D. A phase II Southwest Oncology Group trial (S9714) utilizing paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma of the lung (BAC) [abstract]. Proc ASCO 2001;20:336a.
29. Hsueh EC, Famatiga E, Gupta RK, Qi K, Morton DL. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival. Ann Surg Oncol 1998;5:595-602.
30. Barth A, Hoon DS, Foshaag LJ, Nizze A, Mamatiga E, Okun E, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994;54: 3342-5.
31. Livingston P, Wong G, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
32. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 1999;112:205-9.
33. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997;94:3352-6.
34. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3.
35. Borrello I, Sotomayor E, Cooke S, Levitsky H. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 1999;10: 1983-91.
36. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncosylate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34-42.
37. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;25:623-35.
38. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-20.